| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Gossamer Bio Inc. | GB001 | Eosinophilic asthma | Phase 2b | Trial Discontinued | Oral | Respiratory |
| Gossamer Bio Inc. | GB001 | Nasal polyps / chronic rhinosinusitis | Phase 2 | Trial Discontinued | Oral | Respiratory |
| Gossamer Bio Inc. | Seralutinib (GB002) - (TORREY/PROSERA) | Pulmonary arterial hypertension (PAH) | Phase 3 | Enrollment Conclusion | Inhalation | Cardiology |
| Gossamer Bio Inc. | AKB-4924 (GB004) - (SHIFT-UC) | Ulcerative Colitis | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Gossamer Bio Inc. | RT234 | Pulmonary hypertension (PH), including PAH and PH‚ÄëILD | Phase 3 | Trial Planned | Intranasal | Cardiology |
| Grace Therapeutics Inc. | GTX-104 - (STRIVE-ON) | Subarachnoid hemorrhage (SAH) | PDUFA | Ongoing | Intravenous | Neurology |
| Grace Therapeutics Inc. | GTX-101 | Postherpetic Neuralgia (PHN) | Phase 2 | Topical | Neurology | |
| Grace Therapeutics Inc. | CaPre (TRILOGY 1 and 2) | Hypertriglyceridemia | Phase 3 | oral | Endocrinology |